Dr. Sung jin Kim discovered BAG-2 Gene
<Dr. Sung jin Kim>
Dr. Kim's research paper was published in the December issue of Cell Reports.
Cell Report is a sister journals of the world-renowned scientific journal 'Cell' and is an international journal that publishes research results that cover the entire biotechnology field.
The new title of the paper is 'Co-Chaperone BAG2 Determines Pro-Oncogenic Role of Cathepsin B in Triple-Negative Breast Cancer Cells', a new protein BAG2 involved in cancer formation and metastasis of triple negative breast cancer.
Triple-negative breast cancer is known to be a malignant cancer with a high metastasis to other organs and a recurrence rate of more than 80% within 10 years, but also a refractory cancer with no definite target agent or diagnostic markers for the cause of recurrence or metastasis.
Theragen Etex Bio Institute, in cooperation with Seoul National University's Center for Precision Medical Research, will analyze the genetic information of metastatic breast cancer using Next Generation Sequencing (NGS) technology to determine whether BAG2 gene is involved in metastasis of triple- As a major cause of death.
Animal experiments have shown that inhibition of BAG2 gene expression can completely control the growth and metastasis of trichome-negative breast cancer cells to the lungs. This is due to the fact that BAG2 protein binds to the protein protease 'cathepsin B' It is the first demonstration that it is triggered through interaction.
We also found that BAG2 is a secreted protein that has a higher level of BAG2 protein in the blood of patients with breast cancer than normal and that the survival rate of triple negative breast cancer patients overexpressing BAG2 is significantly lower than that of BAG2 low expression patients.
The present study was conducted to investigate the role of BAG2 protein in the growth and metastasis of triple-negative breast cancer, I look forward to.
This is expected to contribute to the treatment and survival rate of patients with metastatic breast cancer.
Dr. Kim said, "Based on the next-generation genome-based technology, it is meaningful to discover new indicators that can detect changes in the body according to cancer development and cancer metastasis through clinical genomics analysis of cancer patients. "The goal is to bring innovative new drugs and diagnostic technologies targeting BAG2 proteins into pre-clinical trials."